KFDA to extend study period of IPA

The Korea Food and Drug Administration hinted that it will allow more time for manufacturers of painkillers containing isopropylantipyrine (IPA) to prove its safety profile.
On January 12, the drug agency ordered the manufacturers to elucidate the possible link between IPA therapy and adverse events until March next year.

“The study findings will highlight the importance of avoiding the use...